New aspects of haemophilia treatment : 3rd Symposium, September 21-23, 1995, Copenhagen, Denmark
Author(s)
Bibliographic Information
New aspects of haemophilia treatment : 3rd Symposium, September 21-23, 1995, Copenhagen, Denmark
（Haemostasis : international journal on haemostasis and thrombosis research, v. 26 ; suppl. 1）
Karger, c1996
Available at / 2 libraries
-
No Libraries matched.
- Remove all filters.
Description and Table of Contents
Description
This volume presents the proceedings of the Third Symposium on New Aspects of Haemophilia Treatment, held in Copenhagen in September 1995.
Table of Contents
- Part 1 Initiation of haemostasis: cells and the activation of factor VII, L.V.M. Rao and S.I. Rapaport
- monocyte/macrophage regulation of coagulant events, P.B. Tracy et al
- cellular interactions in haemostasis, M. Hoffman et al
- regulation of tissue factor gene expression in human monocytic and endothelial cells, N. Mackman
- the tissue factor - factor VII complex - recent advances towards elucidating the structure and function of the initiator of haemostasis, E.G.D. Tuddenham
- notes on the cell biology of tissue factor, E. Camerer and H. Prydz. Part 2 Regulation of the intiation of haemostasis: influence of the gamma-garboxyglutamic acid-rich domain and hydrophobic stack of factor VIIa on tissue factor binding, E. Persson
- tissue factor interactions - an evaluation using factor VII-factor IX chimeras, J.-Y. Chang
- effect of Ca2+ on the structure and function of factor VIIa, L.C. Peterson and E. Persson
- effect of CA2+ on the structure of vitamin k-dependent coagulation factors, M. Sunnerhagen et al
- computational studies of human prothrombin fragment 1, the Gla domain of factor IX and several biological interesting mutants, L. Li et al. Part 3 Extrinsic coagulation pathway and disease: selectin induction of tissue factor biosynthesis and expression, B. Furie and B.C. Furie
- plasma factor VIIa - measurement and potential clinical significance, J.H. Morrissey
- determinants of coagulation activation in humans, K.A. Bauer et al
- antithrombotic and antilesion benefits without haemorrhagic risks by inhibiting tissue factor pathway, L.A. Harker et al
- role of tissue factor and factor VIIA in the coagulant and inflammatory response to LD100"Escherichia coli" in the baboon, F.B. Taylor, Jr.
- inhibition of tissue factor and cytokine release, E. Gray et al. Part 4 Clinical experience with NovoSeven (rFVIIa): NovoSeven(R)-virus safety, T. Lund Hansen
- long-term follow-up with regard to potential immunogenicity - clinical experience with NovoSeven (recombinant factor VIIa), E.M. Nicolaisen
- dosing and monitoring NovoSeven treatment, U. Hedner
- experience with recombinant factor VIIa in Australia and New Zealand, J. McPherson et al
- major surgery in haemophilic patients with inhibitors using recombinant factor VIIa, J. Ingerslev et al
- NovoSeven compassionate use investigators - recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors, J.M. Lusher
- NovoSeven (recombinant factor VIIa) in central nervous system bleeds, K.M. Rice and G.F. Savidge
- recombinant factor VIIa in joint and muscle bleeding episodes, R. Molskov Bech
- thrombelastgram as a haemostatic monitor during recombinant factor VIIa in haemophilia A patients with inhibitor, A. Yoshioka et al
- American experience with home use of NovoSeven recombinant factor VIIa in haemophiliacs with inhibitors, A.D. Shapiro
- use of recombinant factor VIIa (NovoSeven) in the treatment of two patients affected by type III von (Part contents)
by "Nielsen BookData"